$11.85
-0.49-3.97%
Last update: Oct 23, 7:19 PM
MoonLake Immunotherapeutics (MLTX) Stock Price, Quote, News & History
MLTXNASDAQ
MoonLake Immunotherapeutics (MLTX) announces positive Phase 3 psoriatic arthritis trial results. Cash runway backed through mid-2028.
You can purchase shares of MoonLake (NASDAQ:MLTX) through any online brokerage.
Other companies in MoonLake’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
MoonLake has a consensus price target of $38.56.
The stock price for MoonLake (NASDAQ: MLTX) is $11.99 last updated October 23, 2026 at 7:19 PM EDT.
There are no upcoming dividends for MoonLake.
MoonLake does not have any upcoming earnings scheduled.
There is no upcoming split for MoonLake.
MoonLake is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F...
